Fig. 6: Neutralizing LTα3 promotes weight loss in mice with elevated TNF.
From: Distinct roles for B cell-derived LTα3 and LTα1β2 in TNF-mediated ileitis
a–e, Percent weight change (a) or quantification of cytokines (b–e) including TNF (b), LTα (c), IL-33 (d) and IL-1β (e) of mice comparing day 0 to day 2 in mice transplanted with WT or TNFΔARE/+ BM 9 weeks post-BMT, then dosed with anti-LTα3 antibody or only isotype. f, Percent weight change, comparing day 0 to day 2 in mice transplanted with WT or TNFΔARE/+ BM 9 weeks post-BMT, then dosed with anti-LTα3 antibody, anti-TNF antibody, both or isotype only. g–i, Hydration analysis (g), activity (h) and food intake in the same mice on day 3 (i) dosed again on day 2 after weight assessment were made. j, MRI measurements of body fat composition were also made on these mice on day 3. k, Weights of the gastrocnemius muscle on day 5—the experimental endpoint. g–i, All plots depict mean ± s.e.m. One symbol represents data from one individual mouse. Three independent experiments for a, n = 10 for WT mice and n = 13 for TNFΔARE/+ BM recipients. Two independent experiments for b–k, n = 8 per group. Two-way ANOVA with post hoc Tukey test was used for a–e, h and i to determine whether there was a difference between WT and TNFΔARE/+ mice as well as between isotype and anti-LTα3 treated mice. A one-way ANOVA with post hoc Tukey test was used for f, g, j and k. In all graphs except for c, the P value depicts the results of the post hoc test; in c, the P value shown is the difference between all WT mice and all TNFΔARE/+ BM recipients.
